---
title: "Parenteral Drugs (India) Ltd (PDPL) — Share Price, Financials & Analysis"
symbol: "PDPL"
company: "Parenteral Drugs (India) Ltd"
canonical: "https://tapetide.com/stocks/PDPL"
isin: "INE904D01019"
nse_symbol: "PDPL"
bse_code: "524689"
sector: "Healthcare"
industry: "Pharmaceuticals & Biotechnology"
generated_at: "2026-09-13T18:19:22.938Z"
---

# Parenteral Drugs (India) Ltd (PDPL)

Canonical page: https://tapetide.com/stocks/PDPL

## Company

- **NSE Symbol:** PDPL
- **BSE Code:** 524689
- **ISIN:** INE904D01019
- **Sector:** Healthcare
- **Industry:** Pharmaceuticals & Biotechnology
- **Macro Sector:** Healthcare
- **Stock Type:** EQUITY
- **Listed Since:** 2006-03-01
- **Face Value:** ₹10
- **F&O Eligible:** No
- **Website:** pdindia.com

## About

Incorporated in 1983, Parenteral Drugs Ltd      
is engaged in Manufacturing and Trading of Pharmaceutical Products

## Latest Price

- **Price:** ₹2.9
- **Change:** 0 (0%)
- **Open:** ₹2.7
- **Day High:** ₹2.9
- **Day Low:** ₹2.7
- **Previous Close:** ₹2.9
- **Volume:** 0
- **As Of:** 2023-08-21T04:48:13+00:00

## Key Insights

### Strengths

- Company has reduced debt.

### Weaknesses

- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -48.3% over past five years.
- Contingent liabilities of Rs.135 Cr.
- Company's cost of borrowing seems high

## Growth Rates

| Metric | 1Y | 3Y | 5Y |
| --- | --- | --- | --- |
| net income growth | -6% | 4% | -2% |
| revenue growth | -30% | -36% | -48% |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 9 | 7 | 7 | 9 | 3 | 5 | 2 | 3 | 3 | 2 | 1 | 2 |
| Expenses | 13 | 11 | 10 | 13 | 9 | 11 | 5 | -1 | 6 | 6 | 5 | 8 |
| Operating Profit | -4 | -4 | -3 | -4 | -6 | -6 | -3 | 3 | -3 | -3 | -3 | -6 |
| OPM % | -46 | -50 | -41 | -48 | -200 | -139 | -141 | 132 | -90 | -139 | -224 | -333 |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 52 |
| Interest | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 32 | 34 | 35 | 37 | 0 |
| Depreciation | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 27 |
| Profit before tax | -34 | -35 | -35 | -37 | -40 | -42 | -39 | -33 | -41 | -43 | -44 | 19 |
| Tax % | -19 | -19 | -26 | -13 | -19 | -19 | -21 | -26 | -22 | -22 | -22 | -24 |
| Net Profit | -28 | -28 | -26 | -32 | -32 | -34 | -31 | -25 | -32 | -34 | -35 | 24 |
| EPS in Rs | -9.29 | -9.49 | -8.77 | -10.71 | -10.81 | -11.29 | -10.39 | -8.33 | -10.75 | -11.27 | -11.58 | 7.99 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 327 | 274 | 263 | 260 | 230 | 224 | 32 | 32 | 12 | 8 |
| Expenses | 341 | 349 | 248 | 296 | 249 | 225 | 50 | 47 | 24 | 24 |
| Operating Profit | -14 | -75 | 14 | -36 | -19 | -1 | -18 | -15 | -12 | -15 |
| OPM % | -4.3 | -27 | 5 | -14 | -8 | -0.5 | -55 | -46 | -97 | -177 |
| Other Income | 0 | 107 | 1 | 2 | 3 | 2 | 1 | 0 | 0 | 52 |
| Interest | 56 | 60 | 70 | 70 | 86 | 98 | 96 | 110 | 125 | 106 |
| Depreciation | 23 | 19 | 31 | 23 | 25 | 24 | 69 | 17 | 17 | 40 |
| Profit before tax | -93 | -47 | -86 | -127 | -127 | -121 | -181 | -142 | -154 | -109 |
| Tax % | 16 | -3 | -22 | -8 | -8 | -8 | -18 | -20 | -21 | -30 |
| Net Profit | -108 | -45 | -68 | -117 | -118 | -112 | -148 | -114 | -122 | -76 |
| EPS in Rs | -41.69 | -15.15 | -22.69 | -39.09 | -39.52 | -37.5 | -49.61 | -38.26 | -40.82 | -25.61 |
| Dividend Payout % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Equity Capital | 26 | 30 | 30 | 30 | 30 | 30 | 30 | 30 | 30 | 30 |
| Reserves | 203 | 157 | 82 | 278 | -47 | -166 | -477 | -591 | -713 | -854 |
| Borrowings | 501 | 539 | 581 | 670 | 772 | 767 | 638 | 636 | 636 | 107 |
| Other Liabilities | 105 | 98 | 92 | 88 | 159 | 260 | 349 | 478 | 615 | 1201 |
| Total Liabilities | 835 | 825 | 785 | 1066 | 914 | 890 | 541 | 552 | 568 | 484 |
| Fixed Assets | 610 | 571 | 542 | 892 | 739 | 716 | 356 | 339 | 322 | 205 |
| CWIP | 4 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 2 | 2 | 2 |
| Other Assets | 221 | 253 | 242 | 174 | 175 | 175 | 182 | 210 | 244 | 276 |
| Total Assets | 835 | 825 | 785 | 1066 | 914 | 890 | 541 | 552 | 568 | 484 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash from Operating Activity | -168 | -60 | 2 | 58 | 134 | 167 | 477 | 112 | 125 | 0 |
| Cash from Investing Activity | -18 | 33 | 3 | -110 | -1 | -1 | 97 | 0 | 0 | 65 |
| Cash from Financing Activity | 182 | 25 | -10 | 54 | -134 | -167 | -574 | -112 | -125 | -64 |
| Net Cash Flow | -3 | -2 | -5 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Free Cash Flow | -188 | -38 | -3 | -52 | 134 | 166 | 576 | 112 | 125 | 64 |
| CFO/OP | 1193 | 77 | 12 | -162 | -692 | -14269 | -2700 | -765 | -1065 | 3 |

### Ratios

| Item | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Debtor Days | 88 | 161 | 194 | 130 | 99 | 6 | 0 | 0 | 0 | 0 |
| Inventory Days | 121 | 128 | 232 | 112 | 107 | 68 | 224 | 73 | 103 | 69 |
| Days Payable | 112 | 99 | 177 | 77 | 101 | 130 | 671 | 458 | 504 | 654 |
| Cash Conversion Cycle | 97 | 189 | 249 | 164 | 105 | -55 | -446 | -385 | -401 | -585 |
| Working Capital Days | 22 | 34 | 3 | -198 | -491 | -810 | -9244 | -10747 | -32260 | -48682 |
| ROCE % | -5 | -4 | -2 | -7 | -5 | -3 | -21 | -24 | -213 | — |

## Shareholding Pattern

### annual

| Category | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 |
| --- | --- | --- | --- | --- | --- | --- |
| Promoters | 73.28% | 73.28% | 73.28% | 73.28% | 73.28% | 73.29% |
| DIIs | 0.03% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% |
| Public | 26.69% | 26.71% | 26.71% | 26.71% | 26.71% | 26.71% |
| No. of Shareholders | 7697 | 7519 | 7379 | 7296 | 7269 | 7129 |

### Quarterly

| Category | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Promoters | 73.28% | 73.28% | 73.28% | 73.28% | 73.28% | 73.28% | 73.28% | 73.28% | 73.28% | 73.28% | 73.28% | 73.29% |
| DIIs | 0.01% | 0.01% | 0.03% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% |
| Public | 26.71% | 26.71% | 26.69% | 26.71% | 26.71% | 26.71% | 26.71% | 26.71% | 26.71% | 26.71% | 26.71% | 26.71% |
| No. of Shareholders | 7396 | 7378 | 7330 | 7296 | 7295 | 7300 | 7300 | 7269 | 7205 | 7183 | 7164 | 7129 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Strong Sell
- **Buy / Neutral / Sell:** 2 / 5 / 12

### Moving Averages — summary: **Strong Sell**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 91.71 | Sell |
| EMA (10) | 92.2 | Sell |
| SMA (20) | 100.77 | Sell |
| EMA (20) | 98.46 | Sell |
| SMA (50) | 113.1 | Sell |
| EMA (50) | 111.62 | Sell |
| SMA (100) | 130.39 | Sell |
| EMA (100) | 124.83 | Sell |
| SMA (200) | 153.94 | Sell |
| EMA (200) | 122.03 | Sell |

### Oscillators — summary: **Neutral**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 35.36 | Neutral |
| MACD (12,26,9) | -7.92 | Sell |
| Stochastic (14,3,3) | 15.42 | Buy |
| ADX (14) | 27.85 | Buy |
| Williams %R (14) | -72.24 | Neutral |
| ATR (14) | 5.69 | High Volatility |
| ROC (12) | -16.19 | Sell |
| Stoch RSI (14) | 60.58 | Neutral |
| UO (7,14,28) | 40.39 | Neutral |

## Filings & Documents

### Exchange Filings & Announcements

| Date | Document |
| --- | --- |
| 2025-01-23 | [Corporate Insolvency Resolution Process (CIRP)-Approval of Resolution plan by Tribunal](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=be4b45c6-889d-41a7-9f03-1e1128c188c3.pdf) |
| 2025-01-22 | [Corporate Insolvency Resolution Process (CIRP)-Approval of Resolution plan by Tribunal](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a72814a8-8c16-4164-bf5d-736c5123020a.pdf) |
| 2024-12-07 | [Corporate Insolvency Resolution Process (CIRP)-Outcome of meeting of Committee of Creditors](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0d899a10-7ec1-484b-9e6f-220748b29dd3.pdf) |
| 2024-12-05 | [Corporate Insolvency Resolution Process (CIRP)-Intimation of meeting of Committee of Creditors](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b792d62c-610d-4731-9a4c-20157e68c0b5.pdf) |
| 2024-09-10 | [Corporate Insolvency Resolution Process (CIRP)-Outcome of meeting of Committee of Creditors](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=657eb812-9653-4488-817a-160499cdaa06.pdf) |
| 2024-08-13 | [Corporate Insolvency Resolution Process (CIRP)-Outcome of meeting of Committee of Creditors](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b1eb4969-2806-41df-a45b-734b556e2ac0.pdf) |
| 2024-08-10 | [Corporate Insolvency Resolution Process (CIRP)-Outcome of meeting of Committee of Creditors](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d70555aa-8264-4f49-9f7a-5f76d8b1cd5b.pdf) |
| 2024-08-10 | [Corporate Insolvency Resolution Process (CIRP)-Intimation of meeting of Committee of Creditors](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ee63cf37-b44a-4f30-9b41-31a37e17018c.pdf) |
| 2024-08-09 | [Corporate Insolvency Resolution Process (CIRP)-Intimation of meeting of Committee of Creditors](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=00b7c04e-b9e8-4fee-b2ab-c70c681946e6.pdf) |
| 2024-07-13 | [Corporate Insolvency Resolution Process (CIRP)-Outcome of meeting of Committee of Creditors](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5dc5225a-06bc-47ae-8f2d-47adea805a1f.pdf) |

### Other Documents

| Date | Document |
| --- | --- |
| 7 Dec 2024 - Post-facto intimation of CoC meeting held. | [Corporate Insolvency Resolution Process (CIRP)-Outcome of meeting of Committee of Creditors 7 Dec 2024 - Post-facto intimation of CoC meeting held.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/0d899a10-7ec1-484b-9e6f-220748b29dd3.pdf) |
| 5 Dec 2024 - Meeting of Committee of Creditors scheduled for December 5, 2024. | [Corporate Insolvency Resolution Process (CIRP)-Intimation of meeting of Committee of Creditors 5 Dec 2024 - Meeting of Committee of Creditors scheduled for December 5, 2024.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/b792d62c-610d-4731-9a4c-20157e68c0b5.pdf) |
| 23 Jan 2025 - NCLT approved resolution plan for Parenteral Drugs (India) Ltd. | [Corporate Insolvency Resolution Process (CIRP)-Approval of Resolution plan by Tribunal 23 Jan 2025 - NCLT approved resolution plan for Parenteral Drugs (India) Ltd.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/be4b45c6-889d-41a7-9f03-1e1128c188c3.pdf) |
| 22 Jan 2025 - NCLT approves resolution plan for Parenteral Drugs. | [Corporate Insolvency Resolution Process (CIRP)-Approval of Resolution plan by Tribunal 22 Jan 2025 - NCLT approves resolution plan for Parenteral Drugs.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/a72814a8-8c16-4164-bf5d-736c5123020a.pdf) |
| 10 Sep 2024 - Post-facto intimation of CoC meeting held. | [Corporate Insolvency Resolution Process (CIRP)-Outcome of meeting of Committee of Creditors 10 Sep 2024 - Post-facto intimation of CoC meeting held.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/657eb812-9653-4488-817a-160499cdaa06.pdf) |

### Annual Reports

| Date | Document |
| --- | --- |
| from nse | [Annual Report 2013 from nse](https://archives.nseindia.com/annual_reports/AR_1551_PDPL_2012_2013_10092013115256.zip) |
| from nse | [Annual Report 2011 from nse](https://archives.nseindia.com/annual_reports/AR_PDPL_2010_2011_08092011043838.zip) |
| from bse | [Annual Report 2021 from bse](https://www.bseindia.com/bseplus/AnnualReport/524689/70477524689.pdf) |
| from bse | [Annual Report 2020 from bse](https://www.bseindia.com/bseplus/AnnualReport/524689/65124524689.pdf) |
| from bse | [Annual Report 2019 from bse](https://www.bseindia.com/bseplus/AnnualReport/524689/5246890319.pdf) |
| from bse | [Annual Report 2018 from bse](https://www.bseindia.com/bseplus/AnnualReport/524689/5246890318.pdf) |
| from bse | [Annual Report 2017 from bse](https://www.bseindia.com/bseplus/AnnualReport/524689/5246890317.pdf) |
| from bse | [Annual Report 2016 from bse](https://www.bseindia.com/bseplus/AnnualReport/524689/5246890316.pdf) |
| from bse | [Annual Report 2015 from bse](https://www.bseindia.com/bseplus/AnnualReport/524689/5246890315.pdf) |
| from bse | [Annual Report 2014 from bse](https://www.bseindia.com/bseplus/AnnualReport/524689/5246890314.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T18:19:22.938Z.